Campbell & CO Investment Adviser LLC Sells 4,307 Shares of Aurinia Pharmaceuticals Inc $AUPH

Campbell & CO Investment Adviser LLC trimmed its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 9.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,765 shares of the biotechnology company’s stock after selling 4,307 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Aurinia Pharmaceuticals were worth $337,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in AUPH. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Aurinia Pharmaceuticals by 20.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 12,989 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 2,238 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Aurinia Pharmaceuticals by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 3,497 shares during the last quarter. Virtu Financial LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 38.2% in the first quarter. Virtu Financial LLC now owns 14,727 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 4,074 shares in the last quarter. MAI Capital Management bought a new position in shares of Aurinia Pharmaceuticals in the first quarter valued at approximately $39,000. Finally, Nordea Investment Management AB boosted its position in shares of Aurinia Pharmaceuticals by 1.5% during the second quarter. Nordea Investment Management AB now owns 355,000 shares of the biotechnology company’s stock valued at $3,117,000 after buying an additional 5,400 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Stock Up 0.9%

Aurinia Pharmaceuticals stock opened at $15.35 on Monday. The firm has a 50 day moving average price of $12.60 and a 200-day moving average price of $10.45. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a twelve month low of $6.55 and a twelve month high of $16.20. The company has a market capitalization of $2.02 billion, a P/E ratio of 35.70 and a beta of 1.30.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The business had revenue of $73.47 million for the quarter, compared to the consensus estimate of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Bloom Burton lowered Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $10.00 to $21.00 in a research note on Friday, November 7th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.67.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.